A Phase 2 interventional study of Obeticholic acid in Primary Bile Acid Malabsorption, Secondary Bile Acid Malabsorption and Chronic Diarrhoea, sponsored by Imperial College Healthcare NHS Trust. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-03-10.
Sponsored by Imperial College Healthcare NHS Trust · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The investigators propose to develop studies of obeticholic acid (OCA) in patients with bile acid diarrhoea. OCA is a semisynthetic bile acid, also known as 6αethylchenodeoxycholic acid or INT747,and is a potent farnesoid X receptor (FXR) agonist. Preliminary data suggests that patients with bile acid diarrhoea have impaired production of the ileal hormone Fibroblast Growth Factor 19 (FGF19). FGF19 is stimulated by FXR agonists, and regulates bile acid synthesis. This study is a pilot, proof-of-concept, open-label study to investigate whether OCA can stimulate FGF19 in bile acid diarrhoea patients to provide a safe and effective treatment.
Bile acid diarrhoea (BAD) is an under-recognised but common condition of chronic watery diarrhoea. BAD may be secondary to ileal disease affecting the reabsorption and the enterohepatic circulation of bile acids (bile acid malabsorption) or can be an idiopathic, primary BAD (PBAD). In work published in 2009, we described a new mechanism to explain this syndrome of primary BAD.
Blood levels of the hormone fibroblast growth factor 19 (FGF19) are reduced in primary and secondary BAD, producing impaired feedback inhibition of bile acid synthesis, leading to excess faecal bile acids, which then produce diarrhoea by stimulating colonic secretion. FGF19 is synthesised in the ileum and we have shown transcription is markedly induced by farnesoid X receptor(FXR) agonists such as chenodeoxycholic acid, an abundant natural bile acid. More potent FXR agonists are logical diagnostic and therapeutic agents for this condition, and obeticholic acid (OCA), which is 100x more potent than chenodeoxycholic acid, has recently been developed. It has been used in phase II studies in primary biliary cirrhosis and in non-alcoholic steatohepatitis where a relatively common side-effect was constipation.
We aim to investigate the effects of OCA in patients with primary and secondary BAD to determine whether FGF19 is able to be stimulated in these conditions. We will compare these responses to those in control patients with chronic diarrhoea but without evidence of BAD. It is possible in BAD that the defect in FGF19 levels is due to an inability to respond to FXR stimulation (particularly likely in secondary BAD after ileal resection). Patients with primary BAD may be able to respond and benefit from an increase in FGF19 levels.
This study aims to obtain pilot data on the effects of OCA on FGF19, other markers of bile acid metabolism and patient symptoms including diarrhoea. These are early phase II, proof of concept studies.
Imperial College Healthcare NHS Trust is the lead sponsor of 80 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria Patients aged 18 - 80 who present at routine Gastrointestinal Outpatient Clinics at Hammersmith and Charing Cross Hospitals with chronic diarrhoea, defined as an average stool frequency of at least three per day, of Bristol Stool Type 6 or 7, for at least 3 months. Previous routine SeHCAT testing to establish the presence or absence of bile acid diarrhoea (BAD) unless there is evidence of TI disease/ resection. BAD will be defined as SeHCAT 7-day retention of less than 15% or diarrhoea in presence of TI disease/ resection. Study subjects will be grouped as having secondary BAD, due to ileal resection or Crohn's disease, or primary BAD, with no obvious cause. The third, control group having chronic diarrhoea but with normal SeHCAT retention (greater than 15%).
Female patients must be , surgically sterile, or if premenopausal, be prepared to use ≥ 1 effective (≤ 1% failure rate) method of during the trial and for 15 days after the last dose of OCA. Male subjects with female partners of must use ≥ 1 effective method of contraception. Effective methods of contraception are considered to be: 1. Established use of oral, injected or implanted hormonal methods of contraception. 2. Placement of an intrauterine device (IUD) or intrauterine system (IUS). 3. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository. 4. Male sterilisation (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate). 5. True abstinence: When this is in line with the preferred and usual lifestyle of the subject.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Defined as SeHCAT \<10% without other causes such as Crohn's disease and/or ileal resection
Drug: Obeticholic acid
With Crohn's disease or ileal resection
Drug: Obeticholic acid
Chronic diarrhoea with SeHCAT \>15% and no Crohn's or ileal resection
Drug: Obeticholic acid
Day -14 to Day 0 subjects will stop their usual diarrhoeal medication. Day 1 to Day 15 Obeticholic acid 25mg tablet will be administered to subjects once daily in the morning. Day 16 to day 28 normal diarrhoeal medication may be re-commenced.
Also known as: INT-747, 6 ethyl chenodeoxycholic acid
Changes in Fasting FGF19
The primary outcome measure is the change over 2 weeks in fasting serum fibroblast growth factor (FGF19) in 3 groups of patients: primary bile acid diarrhoea, secondary bile acid diarrhoea, and a control population of patients with chronic diarrhoea but with normal bile acid retention.
Time frame: Day 0, Day 15
Changes in Non-fasting Response of FGF19 to OCA
Change in dynamic response of FGF19 in 6 hours following OCA administration; at start and end of 15 day OCA test period.
Time frame: Day 0, Day 15
Changes in Fasting 7α-hydroxy-4-cholesten-3-one
Change in fasting 7α-hydroxy-4-cholesten-3-one before and after 15 day administration of OCA.
Time frame: Day 0, Day 15
Changes in Serum Total Bile Acids.
Dynamic changes of total bile acids over 6 hour period following OCA administration before and after 15 day OCA period.
Time frame: Day 0, Day 15
Changes in Stool Frequency
Change in total number of stool episodes reported per week between week 2 (baseline) and week 4 (week 2 of treatment)
Time frame: Week 2, Week 4
Changes in Mean Stool Form
Change in mean stool form reported per week between week 2 (baseline) and week 4 (week 2 of treatment) using the Bristol Stool Form Scale (range of scores 1 to 7). High scores are a worse outcome (7=liquid stools).
Time frame: Week 2, Week 4
Change in Stool Index
Change in index calculated on a weekly basis, between week 2 (baseline) and week 4 (week 2 of treatment). Index calculated as (\[weekly stool frequency x mean Bristol Stool Form Scale score\] = Loperamide use \[weekly mg x 3\]). Individual scores ranged from 25 to 1095, with higher scores being worst.
Time frame: Week 2, Week 4
| Milestone | Primary BAD | Secondary BAD | Idiopathic Diarrhoea Controls |
|---|---|---|---|
| Started | 10 | 13 | 12 |
| Completed | 10 | 10 | 8 |
| Not completed | 0 | 3 | 4 |
| Withdrew: Withdrawal by subject | 0 | 3 | 4 |
The primary outcome measure is the change over 2 weeks in fasting serum fibroblast growth factor (FGF19) in 3 groups of patients: primary bile acid diarrhoea, secondary bile acid diarrhoea, and a control population of patients with chronic diarrhoea but with normal bile acid retention.
| percentage increase of baseline | Primary BAD | Secondary BAD | Idiopathic Diarrhoea Controls |
|---|---|---|---|
| Changes in Fasting FGF19 | 71 (9 to 102) | 25 (-6 to 140) | 130 (-14 to 304) |
Change in dynamic response of FGF19 in 6 hours following OCA administration; at start and end of 15 day OCA test period.
| percentage change | Primary BAD | Secondary BAD | Idiopathic Diarrhoea Controls |
|---|---|---|---|
| Changes in Non-fasting Response of FGF19 to OCA | 11.6 (-23.6 to 57.8) | 14.6 (-22.7 to 49.0) | 32.4 (15.1 to 38.4) |
Change in fasting 7α-hydroxy-4-cholesten-3-one before and after 15 day administration of OCA.
| microgram/L | Primary BAD | Secondary BAD | Idiopathic Diarrhoea Controls |
|---|---|---|---|
| Changes in Fasting 7α-hydroxy-4-cholesten-3-one | -11.5 (-30.0 to -3.5) | -27.5 (-56.3 to 0) | -6.5 (-11.5 to -1.5) |
Dynamic changes of total bile acids over 6 hour period following OCA administration before and after 15 day OCA period.
| micromol/L | Primary BAD | Secondary BAD | Idiopathic Diarrhoea Controls |
|---|---|---|---|
| Changes in Serum Total Bile Acids. | -18.1 (-33.0 to -5.50) | -2.0 (-17.5 to 0.08) | -15.5 (-17.9 to -14.0) |
Change in total number of stool episodes reported per week between week 2 (baseline) and week 4 (week 2 of treatment)
| stools per week | Primary BAD | Secondary BAD | Idiopathic Diarrhoea Controls |
|---|---|---|---|
| Changes in Stool Frequency | -4.5 (-9.3 to -1.5) | -2.5 (-15.8 to 1.8) | 3.0 (-3.0 to 7.0) |
Change in mean stool form reported per week between week 2 (baseline) and week 4 (week 2 of treatment) using the Bristol Stool Form Scale (range of scores 1 to 7). High scores are a worse outcome (7=liquid stools).
| Score on Bristol scale | Primary BAD | Secondary BAD | Idiopathic Diarrhoea Controls |
|---|---|---|---|
| Changes in Mean Stool Form | -0.71 (-1.54 to 0.10) | -0.38 (-0.91 to -0.18) | -0.46 (-0.91 to 0.86) |
Change in index calculated on a weekly basis, between week 2 (baseline) and week 4 (week 2 of treatment). Index calculated as (\[weekly stool frequency x mean Bristol Stool Form Scale score\] = Loperamide use \[weekly mg x 3\]). Individual scores ranged from 25 to 1095, with higher scores being worst.
| index score | Primary BAD | Secondary BAD | Idiopathic Diarrhoea Controls |
|---|---|---|---|
| Change in Stool Index | -37.5 (-52.3 to -22.8) | -32.5 (-158.6 to -13.4) | -5.5 (-30.0 to 20.0) |
Collected over Data were collected over the 6 weeks of the trial. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Primary BAD | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Secondary BAD | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Idiopathic Diarrhoea Controls | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Event | Primary BAD | Secondary BAD | Idiopathic Diarrhoea Controls |
|---|---|---|---|
| HeadacheNervous system disorders | 0/10 | 2/10 | 1/8 |
| Constipation/abdominal painGastrointestinal disorders | 0/10 | 1/10 | 0/8 |
Received any dose of medication
| Age, Continuous(years) | Primary BAD | Secondary BAD | Idiopathic Diarrhoea Controls | Total |
|---|---|---|---|---|
| Median | 47 (24 to 74) | 45 (27 to 71) | 39 (25 to 68) | 41 (24 to 74) |
| Sex: Female, Male(Participants) | Primary BAD | Secondary BAD | Idiopathic Diarrhoea Controls | Total |
|---|---|---|---|---|
| Female | 7 | 7 | 3 | 17 |
| Male | 3 | 3 | 5 | 11 |
| Region of Enrollment(participants) | Primary BAD | Secondary BAD | Idiopathic Diarrhoea Controls | Total |
|---|---|---|---|---|
| United Kingdom | 10 | 10 | 8 | 28 |
Plan to share: No
The record gives a start of Apr 2012, a primary completion of Jan 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2019, 5 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obeticholic acid
Imperial College Healthcare NHS Trust